JP2019500012A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500012A5
JP2019500012A5 JP2018522004A JP2018522004A JP2019500012A5 JP 2019500012 A5 JP2019500012 A5 JP 2019500012A5 JP 2018522004 A JP2018522004 A JP 2018522004A JP 2018522004 A JP2018522004 A JP 2018522004A JP 2019500012 A5 JP2019500012 A5 JP 2019500012A5
Authority
JP
Japan
Prior art keywords
cell
seq
cells
polypeptide
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522004A
Other languages
English (en)
Japanese (ja)
Other versions
JP7104624B2 (ja
JP2019500012A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/059444 external-priority patent/WO2017075433A1/en
Publication of JP2019500012A publication Critical patent/JP2019500012A/ja
Publication of JP2019500012A5 publication Critical patent/JP2019500012A5/ja
Priority to JP2022110653A priority Critical patent/JP7539434B2/ja
Application granted granted Critical
Publication of JP7104624B2 publication Critical patent/JP7104624B2/ja
Priority to JP2024134780A priority patent/JP2024155943A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522004A 2015-10-30 2016-10-28 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 Active JP7104624B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022110653A JP7539434B2 (ja) 2015-10-30 2022-07-08 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法
JP2024134780A JP2024155943A (ja) 2015-10-30 2024-08-13 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248685P 2015-10-30 2015-10-30
US62/248,685 2015-10-30
PCT/US2016/059444 WO2017075433A1 (en) 2015-10-30 2016-10-28 Transforming growth factor-beta-responsive polypeptides and their methods for use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022110653A Division JP7539434B2 (ja) 2015-10-30 2022-07-08 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019500012A JP2019500012A (ja) 2019-01-10
JP2019500012A5 true JP2019500012A5 (OSRAM) 2019-12-05
JP7104624B2 JP7104624B2 (ja) 2022-07-21

Family

ID=58631218

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018522004A Active JP7104624B2 (ja) 2015-10-30 2016-10-28 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法
JP2022110653A Active JP7539434B2 (ja) 2015-10-30 2022-07-08 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法
JP2024134780A Pending JP2024155943A (ja) 2015-10-30 2024-08-13 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022110653A Active JP7539434B2 (ja) 2015-10-30 2022-07-08 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法
JP2024134780A Pending JP2024155943A (ja) 2015-10-30 2024-08-13 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法

Country Status (17)

Country Link
US (2) US11014980B2 (OSRAM)
EP (2) EP3368571B1 (OSRAM)
JP (3) JP7104624B2 (OSRAM)
KR (1) KR102771979B1 (OSRAM)
CN (2) CN108884155B (OSRAM)
DK (1) DK3368571T5 (OSRAM)
ES (1) ES2935372T3 (OSRAM)
FI (1) FI3368571T3 (OSRAM)
HR (1) HRP20230239T1 (OSRAM)
HU (1) HUE061424T2 (OSRAM)
LT (1) LT3368571T (OSRAM)
PL (1) PL3368571T3 (OSRAM)
PT (1) PT3368571T (OSRAM)
RS (1) RS64053B1 (OSRAM)
SI (1) SI3368571T1 (OSRAM)
SM (1) SMT202300027T1 (OSRAM)
WO (1) WO2017075433A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
SI3240805T1 (sl) 2014-12-15 2025-04-30 The Regents Of The University Of California Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20
SMT202300027T1 (it) * 2015-10-30 2023-05-12 Univ California Polipeptidi sensibili al fattore di crescita trasformante beta e le loro modalità d’uso
EP3439698A1 (en) * 2016-04-05 2019-02-13 GlaxoSmithKline Intellectual Property Development Ltd Inhibition of tgfbeta in immunotherapy
US11701384B2 (en) 2016-09-02 2023-07-18 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
CA3068550A1 (en) * 2017-06-30 2019-01-03 Kolon Life Science, Inc. Pharmaceutical composition for preventing or treating osteoarthritis
CN109486745A (zh) * 2017-09-12 2019-03-19 中国人民解放军第三军医大学第附属医院 Fg-4592在促进表皮干细胞迁移方面的应用
CN111684061B (zh) * 2018-01-19 2024-07-30 美天施生物科技有限两合公司 表达嵌合抗原受体的调节性t细胞
GB201807693D0 (en) * 2018-05-11 2018-06-27 Autolus Ltd Cell
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
JP2022545167A (ja) * 2019-08-30 2022-10-26 アロジーン セラピューティクス,インコーポレイテッド Tgfベータ結合ドメインを含むキメラサイトカイン受容体
CN111748043B (zh) * 2020-07-03 2022-09-02 深圳市体内生物医药科技有限公司 一种嵌合抗原受体及其应用
CA3193009A1 (en) * 2020-08-26 2022-03-03 The Regents Of The University Of California Methods and compositions for treating glioblastoma
CN112500491B (zh) * 2020-12-18 2022-04-08 深圳市迈加瑞生物技术有限公司 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
US20240336903A1 (en) * 2021-08-19 2024-10-10 Shandong Boan Biotechnology Co., Ltd. Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway
WO2023201206A1 (en) * 2022-04-11 2023-10-19 The Board Of Trustees Of The Leland Stanford Junior University Cytokine adaptor proteins and uses thereof
EP4509522A1 (en) 2023-08-16 2025-02-19 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft A tgfbeta switch receptor, a nucleic acid encoding it, cells and pharmaceutical compositions comprising the same
WO2025096419A1 (en) * 2023-10-31 2025-05-08 Lyell Immunopharma, Inc. T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
AU7274898A (en) 1997-05-07 1998-11-27 Bristol-Myers Squibb Company Recombinant antibody-enzyme fusion proteins
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US7066469B2 (en) 2002-08-06 2006-06-27 University of Kentucky Research Foundation Board of Supervisors of Louisiana State University Seal assembly for machinery housing
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US20050125852A1 (en) * 2003-05-09 2005-06-09 Sugen, Inc. Novel kinases
JP2007515949A (ja) 2003-11-13 2007-06-21 ジェネンテック・インコーポレーテッド スクリーニングアッセイ及び腫瘍治療の方法
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
EP1810980A1 (en) 2004-10-28 2007-07-25 Osaka University Interleukin-6 inhibitors
EP1850873B1 (en) 2005-02-08 2018-11-28 Genzyme Corporation Antibodies to tgfbeta
WO2007070866A2 (en) 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
WO2009019441A2 (en) * 2007-08-03 2009-02-12 Asterion Limited Granulocyte colony stimulating factor
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
MY165160A (en) 2010-09-01 2018-02-28 Genzyme Corp TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
EP4011913A1 (en) * 2011-06-30 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
BR112015021595A2 (pt) 2013-03-11 2017-10-10 Genzyme Corp anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno
EP2986636B1 (en) * 2013-04-17 2018-11-14 Baylor College Of Medicine Immunosuppressive tgf-beta signal converter
MX370272B (es) * 2014-03-19 2019-12-09 Cellectis Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
CA2944528C (en) * 2014-04-03 2021-08-10 Cellectis Cd33 specific chimeric antigen receptors for cancer immunotherapy
CA2945620C (en) * 2014-04-14 2022-12-06 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
SI3240805T1 (sl) 2014-12-15 2025-04-30 The Regents Of The University Of California Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
SMT202300027T1 (it) * 2015-10-30 2023-05-12 Univ California Polipeptidi sensibili al fattore di crescita trasformante beta e le loro modalità d’uso
KR20230148844A (ko) 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
CN108148863B (zh) 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用

Similar Documents

Publication Publication Date Title
JP2019500012A5 (OSRAM)
Larson et al. Recent advances and discoveries in the mechanisms and functions of CAR T cells
JP7700159B2 (ja) Axlまたはror2に対するキメラ抗原受容体およびその使用方法
US20250034217A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
Chmielewski et al. TRUCKs: the fourth generation of CARs
HRP20230239T1 (hr) Polipeptidi koji reagiraju na transformirajući faktor rasta – beta i postupci za njihovu upotrebu
Lian et al. Challenges and recent advances in NK cell-targeted immunotherapies in solid tumors
JP6557657B2 (ja) 分子
JP2023093469A (ja) 抗cd16a抗体のサイトカインとの組み合わせ
Kim et al. Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7
JP2022166297A (ja) 最適化された多機能性t細胞を含むキメラ受容体t細胞を使用する治療
US12448426B2 (en) Chimeric antigen receptors with MYD88 and CD40 costimulatory domains
JP2015508816A (ja) Ox40アゴニスト/il−2二重癌治療法
JP2023071724A (ja) Cmvエピトープ
JP2024016200A (ja) キメラ抗原受容体療法のt細胞の増殖動態及びその使用
WO2022037562A1 (en) Engineered immunoresponsive cells and uses thereof
JP2025128204A (ja) 免疫細胞機能の改善
JP2023538012A (ja) 免疫細胞機能の改善
TW202309269A (zh) 重組抗原呈現細胞
WO2023006975A2 (en) Chimeric proteins and methods of immunotherapy
CN117412989A (zh) 具有改进的特性的双功能分子的新支架
JP2020535832A (ja) マウス定常領域を伴うtcrを発現する細胞を選択的に増幅するための方法
JP2022523554A (ja) T細胞受容体及びその使用方法
WO2020242837A1 (en) A precision medicine method for cancer immunotherapy
JP2022524994A (ja) T細胞受容体及びその使用方法